Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594100 · ClinicalTrials.gov registry record · Phase 3
GORE Embolic Protection With Reverse Flow
A Phase 3 study of Carotid Artery Stenosis, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 2
- Study locations
NCT00594100: Completed Phase 3 study of Carotid Artery Stenosis, sponsored by W.L.Gore & Associates.
NCT00594100 is a Phase 3 study of Carotid Artery Stenosis that has completed, run by W.L.Gore & Associates. The registered enrollment target is 245 participants, below the 285-participant average among 4 other Carotid Artery Stenosis trials with a reported enrollment target (14% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00594100, a Phase 3 study of Carotid Artery Stenosis, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 2
- Study locations
Study Summary
To compare the 30-day safety and efficacy of the GORE Flow Reversal System when used with approved carotid stents to an Objective Performance Criterion derived from distal embolic protection studies.
Primary Outcome
Number of participants with one or more Major Adverse Event (death, stroke, myocardial infarction, and/or transient ischemic attack (TIA)) through the 30-day follow-up (non-hierarchical; MAE adjudicated by independent Clinical Events Committee)
Conditions Studied
Interventions
- DEVICE GORE Flow Reversal System (GFRS)
Study Locations (2)
New York
- Millard Fillmore Gates/Univ. of Buffalo - Buffalo
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
What the finished NCT00594100 record still lists
NCT00594100 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 285-participant average among 4 other Carotid Artery Stenosis trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Carotid Artery Stenosis appearing as the primary indexed condition, and to 1 intervention - of which GORE Flow Reversal System (GFRS) is the first listed.
NCT00594100 reports a single indexed study location in New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT00594100 about?
NCT00594100 is a clinical study titled "GORE Embolic Protection With Reverse Flow". To compare the 30-day safety and efficacy of the GORE Flow Reversal System when used with approved carotid stents to an Objective Performance Criterion derived from distal embolic protection studies.
What is the current status of trial NCT00594100?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2006-07. Estimated completion is 2008-09.
What conditions does trial NCT00594100 study?
This clinical trial studies the following conditions: Carotid Artery Stenosis.
What interventions are being tested in trial NCT00594100?
The interventions under investigation include: GORE Flow Reversal System (GFRS) (DEVICE).
Who is sponsoring clinical trial NCT00594100?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00594100 being conducted?
This trial has 2 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carotid Artery Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting
ACTIVE NOT RECRUITING · NA
-
Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System
ACTIVE NOT RECRUITING · NA
-
The Gore SCAFFOLD Clinical Study
COMPLETED · NA
-
Long-term Neurocognitive Sequelae of Subclinical Microembolization During Carotid Interventions
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia